Physicians' Academy for Cardiovascular Education

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK

Results of ODYSSEY OUTCOMES and FOURIER trials complement each other

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Steven Nissen, MD - Cleveland, OH, USA

Messages from the ODYSSEY OUTCOMES trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Prof. Kausik Ray, Imperial College Londen, UK

Results with PCSK9 inhibitor in ODYSSEY OUTCOMES above expectations, mortality benefit included

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL. USA - Prof. Wouter Jukema - LUMC, The Netherlands

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg, Paris, France

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

10' education - Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017 - Online CME

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017

Diverse study data confirm the rationale of intensive lipid-lowering

3' education - Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS

Imaging components of plaque not more informative than burden of plaque

3' education - Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective

3' education - Aug. 28, 2017

LDL-c still reduced after 1 year with siRNA against PCSK9

3' education - Aug. 28, 2017

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Changing therapeutic behaviour after FOURIER

10' education - Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

10' education - Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

10' education - Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

10' education - Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

10' education - Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

LDL lowering for CVD prevention: From hypothesis to axiom

10' education - Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

10' education - Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

3' education - Mar. 17, 2017

EC approves PCSK9 inhibitor for patients with established atherosclerotic CVD

News - May 16, 2018

The European Commission (EC) has approved the use of evolocumab in patients with established atherosclerotic CVD (MI, stroke, PAD) to reduce CV risk.

PCSK9 RNA interference causes significant and sustained lipid reductions

Literature - May 9, 2018 - Ray KK et al. - Circulation 2018

Inhibition of hepatic PCSK9 synthesis with the small interfering RNA inclisiran led to significant reductions of non-HDL-c and apoB, and increases of HDL-c, which were sustained up to day 180.

PCSK9 RNA silencing agent now tested in multiple dyslipidemia populations

News - May 2, 2018

New ORION-data shows inclisiran has a one-size-fits-all dosing regimen of 300 mg on day 1, day 90 and every six months thereafter, across a wide range of dyslipidemia patients, including HoFH.

Conventional lipid-lowering therapy is not effective enough for heFH patients

Literature - May 1, 2018 - Hartgers ML et al., - J Clin Lipidol. 2018

A model assuming 100% adherence to maximal statin dose showed that only 10% of heFH patients with CHD would reach guideline-recommended LDL-c goal, and about half of those without CHD.

Large interpersonal variation in estimated benefit from PCSK9 inhibition in CAD patients

Literature - Apr. 26, 2018 - Kaasenbrood L et al. - Heart 2018

The potential incremental benefit of PCSK9 inhibition varies a lot among patients with stable CAD, with the greatest benefit observed in younger patients with highest risk factor burden and high LCL-c levels.

Greater risk reduction with PCSK9 inhibition in readily ascertainable high risk patient subgroups

Literature - Apr. 18, 2018 - Sabatine MS et al. - Circulation. 2018
Patients with a history of MI who are closer to their most recent event, have had multiple prior MIs or have residual multi-vessel CAD, had higher CV risk reductions with evolocumab.

Patients with a history of MI who are closer to their most recent event, have had multiple prior MIs or have residual multi-vessel CAD, had higher CV risk reductions with evolocumab.

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK
Atherogenic dyslipidemia increases CV risk in diabetes patients. Prof. Ray discusses the importance of dyslipidemia in these patients, the associated CV risk and new medical therapies to reduce this risk.

Atherogenic dyslipidemia increases CV risk in diabetes patients. Prof. Ray discusses the importance of dyslipidemia in these patients, the associated CV risk and new medical therapies to reduce this risk.

A PCSK9 inhibitor lowers LDL-c in patients with gene mutations that are causative for FH

Literature - Apr. 5, 2018 - Hartgers ML, et al. - J Clin Lipidol 2018

A clinically meaningful LDL-c-lowering activity was observed in patients receiving alirocumab who are double or compound heterozygous, or homozygous for genes that are causative for FH.

Phase 2 study with cholesterol biosynthesis inhibitor on top of PCSK9 inhibitor meets primary endpoint

News - Mar. 27, 2018

Treatment with bempedoic acid lowers LDL-c by an additional 30% when added to evolocumab treatment in patients with hypercholesterolemia.

PCSK9 inhibition lowers Lp(a) concentration by a dual mechanism of action

Literature - Mar. 27, 2018 - Watts GF, et al. - Eur Heart J 2018

PCSK9 inhibition decreases the production and in combination with atorvastatin increases the clearance of Lp(a) particles, confirming a dual mechanism of action that lowers plasma Lp(a) concentration.

Lowering of Lp(a)-c results in lower LDL-c measurements, but constant true LDL-c levels

Literature - Mar. 26, 2018 - Viney NJ, et al. - J Clin Lipidol 2018
In a phase 2 study in patients with elevated Lp(a), measured LDL-c included circulating Lp(a)-c and lowering of Lp(a)-c led to lower LDL-c measurements and constant ‘true’ LDL-c levels.

In a phase 2 study in patients with elevated Lp(a), measured LDL-c included circulating Lp(a)-c and lowering of Lp(a)-c led to lower LDL-c measurements and constant ‘true’ LDL-c levels.

Positive CHMP opinion for PCSK9 inhibitor to reduce CV risk in high-risk patients

News - Mar. 26, 2018

Following the results from the FOURIER trial, EMA’s CHMP has issued a positive opinion for the PCSK9 inhibitor evolocumab to reduce CV risk in patients with established ASCVD.

PCSK9
PCSK9
PCSK9